Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
The Oncologist
|
February 6, 2026
Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer
Krishny Karunanandaa, Eric Marshall Knoche, Robert Bruce Montgomery, et al.
European Urology Oncology
|
May 24, 2025
Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency
Ruben Raychaudhuri, Heather H Cheng, Roman Gulati, et al.
Diagnostic Microbiology and Infectious Disease
|
March 27, 2014
A rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein-glycolipid conjugate
Malcolm S Duthie, Ruben Raychaudhuri, Yeung L Tutterrow, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 12, 2026
Prognostic Value of Cycle 1 SPECT SUV<sub>mean</sub> in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617
Alireza Ghodsi, Ridvan A Demirci, Roman Gulati, et al.
JCO Precision Oncology
|
April 25, 2024
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to <sup>177</sup>Lu-PSMA-617: A Retrospective Multicenter Cohort Study
Ruben Raychaudhuri, George Mo, Abuzar Moradi Tuchayi, et al.
Radiology
|
March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617
Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
European Urology Oncology
|
February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
Ruben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
The Oncologist
|
October 22, 2025
Genomic Alterations and Associated Outcomes in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer treated with 177Lu-PSMA-617
Justine Panian, Nicholas C Henderson, Daniel Herchenhorn, et al.
JCO Precision Oncology
|
December 5, 2025
Impact of <i>SPOP</i> Mutations on Clinical Outcomes in Metastatic Prostate Cancer
Deepak Kilari, Nicholas C Henderson, Kyra Yamamoto, et al.
European Urology
|
August 5, 2025
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial
Ruben Raychaudhuri, Ali Raza Khaki, Mary W Redman, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
The Oncologist
|
February 6, 2026
Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer
Krishny Karunanandaa, Eric Marshall Knoche, Robert Bruce Montgomery, et al.
European Urology Oncology
|
May 24, 2025
Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency
Ruben Raychaudhuri, Heather H Cheng, Roman Gulati, et al.
Diagnostic Microbiology and Infectious Disease
|
March 27, 2014
A rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein-glycolipid conjugate
Malcolm S Duthie, Ruben Raychaudhuri, Yeung L Tutterrow, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 12, 2026
Prognostic Value of Cycle 1 SPECT SUV<sub>mean</sub> in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617
Alireza Ghodsi, Ridvan A Demirci, Roman Gulati, et al.
JCO Precision Oncology
|
April 25, 2024
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to <sup>177</sup>Lu-PSMA-617: A Retrospective Multicenter Cohort Study
Ruben Raychaudhuri, George Mo, Abuzar Moradi Tuchayi, et al.
Radiology
|
March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617
Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
European Urology Oncology
|
February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
Ruben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
The Oncologist
|
October 22, 2025
Genomic Alterations and Associated Outcomes in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer treated with 177Lu-PSMA-617
Justine Panian, Nicholas C Henderson, Daniel Herchenhorn, et al.
JCO Precision Oncology
|
December 5, 2025
Impact of <i>SPOP</i> Mutations on Clinical Outcomes in Metastatic Prostate Cancer
Deepak Kilari, Nicholas C Henderson, Kyra Yamamoto, et al.
European Urology
|
August 5, 2025
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial
Ruben Raychaudhuri, Ali Raza Khaki, Mary W Redman, et al.
Page
of 3